AstraZeneca Announced to Conduct Clinical Trial for PAD

AstraZeneca introduced intends to conduct the EUCLID study, a worldwide clinical trial with 11,500 affected individuals with peripheral artery disease (PAD), a disease affecting about 27 million people in European continent and North America. PAD affected individuals are at higher risk of myocardial infarction (MI), strokes, along with other health complications. EUCLID requires evaluate cardiovascular (CV) event speed and safety in PAD affected individuals. Ticagrelor at this moment not approved regarding the treatment of affected individuals with PAD.

"The worldwide burden of PAD is one where it necessitates further study of additional methods of treatment that may further decrease the danger of atherothrombotic CV events and CV death," said William Hiatt, MD, Professor of Medicine, Division of Cardiology, and University of Colorado School of Medicine. "The EUCLID survey is definitely an exciting clinical trial, as it could put together further clinical evidence with regard to the role oral anti-platelets can engage in reducing risk for affected individuals with PAD."

EUCLID serves as a randomized, double-blind, parallel collection of people, multi-center study sensing the performance of ticagrelor (monotherapy) in comparison with clopidogrel (monotherapy) in reducing the first endpoint - an amalgamated of CV death, MI or ischemic stroke - in affected individuals with PAD.

In the EUCLID study, characteristic PAD affected individuals who are 50 years of age or more aged will certainly be randomized to obtain either ticagrelor 90 mg two times daily or clopidogrel 75 mg once daily. Once plans to initiate the study have been completed, the EUCLID steering group will begin the method of recruiting survey investigators, medical centers, and subsequently affected individuals.